Oxcarbazepine Tablet, Film Coated
Product Images NDC 55154-4320

This text contains information about OXCARBAZEPINE TABLETS, USP 300 mg. Each film-coated tablet contains 300 mg of oxcarbazepine. The usual dosage and complete prescribing information can be found in the product insert. Storage instructions indicate that the tablets should be stored at a temperature between 20°C - 25°C (77°F) with excursions permitted to 15°C - 30°C (59°F - 86°F). The medication contains FD&C Yellow No. 5 (tartrazine) as a color additive. The text also mentions that the packaging is not child resistant and is intended for institutional use only. The manufacturer is LGM Pharma Solutions, LLC, based in Irvine, CA. The distribution is handled by Breckenridge Pharmaceutical Inc. and Major Pharmaceuticals, with distribution by Cardinal Health.*

Oxcarbazepine Tablets, USP 150 mg is a medication that contains 10 film-coated tablets with each tablet containing 150 mg of oxcarbazepine. This medication is typically used to treat certain types of seizures in patients with epilepsy. The usual dosage and complete prescribing information can be found in the product insert. It is recommended to store the medication at a temperature between 20°C to 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The package includes an insert with additional medical guidance, which can be found at vww.majorpharmaceuticals.com. The medication contains FDAC Yellow No. 5 (tartarzine) as a color additive and is only available with a prescription. The unit dose packaging is not child resistant and is intended for institutional use only. It is essential to keep this and all drugs out of the reach of children and dispense them in a tight container. The medication is manufactured by LGM Pharma Solutions, LLC in Irvine, CA, and distributed by Brockenridge Pharmaceutical Inc in Berlin, CT. It is packaged and distributed by Major Pharmaceuticals in Indianapolis, IN, and distributed by Cardinal Health in Dublin, OH. Unfortunately, the provided text does not provide clear information on how to use the medication or possible side effects.*

This text provides information about the seizure rate and statistical analysis related to a treatment group. The log-rank test was conducted, resulting in a p-value of 0.045. The table shows the days from the first dose to the first seizure for both the Oxcarbazepine and Placebo treatment groups.*

The text provided is not readable.*

This text appears to be a result from a statistical test, specifically a Tog-rank test. The given p-value is 0.0001. The text also includes a chart with a time scale labeled from 0 to 130, and a treatment group labeled as HIGH and LOW.*